Alerta

RESPIRATORY SIMULATION SYSTEM INCLUDING AN ANATOMICAL MODEL OF THE HUMAN NASAL CAVITY CONFIGURED FOR IN-VITRO INHALATION STUDIES AND ASSOCIATED METHODS

Resumen de: US20260287578A1

The anatomical model of a nasal cavity, such as a human nasal cavity, for in-vitro inhalation studies such as toxicological screening, intranasal drug delivery studies, and neurophysiological studies. The model includes a model body including separable upper and lower model portions together defining the nasal cavity and including fluidic channels therein that define an olfactory region of the upper model portion, and a nasal passage defined in the lower model portion. A biocompatible porous membrane is positioned between the upper and lower model portions, and the biocompatible membrane is configured for culturing olfactory epithelium cells thereon. An artificial mucous layer coats a surface of the nasal cavity and is configured to collect particles passing through the nasal cavity.

METHODS, DEVICES, AND SYSTEMS FOR DETECTING ANALYTE LEVELS

Resumen de: US20260289785A1

0000 The present disclosure describes a method of quantifying analyte levels using gold nanoparticles. The present disclosure also describes a device to quantify analyte levels using gold nanoparticles and image processing of pixels isolated from a single vector. The methods, devices, and systems of the disclosure can be used to quantify analytes such as luteinizing hormone, progesterone, estradiol, or testosterone.

High-sensitivity Assay for Serum Neurofilament Light Chain

Resumen de: US20260287580A1

0000 The present disclosure provides methods and kits for identifying and treating individuals at risk of or suffering from disease such as a neurological condition or disease. In general, detection or measurement of one or more biomarkers, such as neurofilament light chain (NfL), and combinations thereof with assays of the present disclosure, assists in the identification of disease such as neurological disease. The present disclosure also provides methods for selecting patients for treatment of neurological disease.

SAPONIN DERIVATIVES AS ADJUVANTS AND PHOTOAFFINITY PROBES

Resumen de: US20260285898A1

The present application relates to compounds based on a triterpene glycoside saponin scaffold, which bear an acyl chain comprising a photoreactive moiety and a terminal biotin, of general formula (I)The present application also relates to the use of said compounds and compositions thereof in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers as well as its use as chemical probe in photoaffinity labeling (PAL) (for photocrosslinking with interacting partners) followed by affinity purification of the covalent complex and MS-based proteomics for target identification and elucidation of the protein receptor.

POTENCY ASSAY MATRIX FOR NEURONAL CELLS

Resumen de: US20260287576A1

0000 The invention provides, in some embodiments, a potency assay matrix for assessing potency of dopaminergic neuronal progenitor cells (DANPCs) that are intended for use in treating a neurodegenerative disease such as Parkinson's Disease. The potency assay matrix can include a bioassay for L-DOPA decarboxylase (DDC) activity. In addition to the DDC activity assay matrix, the potency assay matrix may also include one or more additional mechanism of action-based assays such as bioinformatics-based assays for determining whether the DANPCs are dopaminergic neuronal progenitor cells, for determining whether the DANPCs are likely to engraft when implanted into a subject brain, and for determining whether neuronal cells that are derived from the DANPCs are likely to produce dopamine after implantation.

VERSATILE IMMUNODIAGNOSTIC SMARTPHONE-BASED TOOL FOR ASSESSMENT

Resumen de: WO2026198565A1

A method and related system for immunodiagnostic assessment of an antigen in a sample. A sample is mixed in a sample tube (i.e., cartridge) with magnetic beads and first visualization reagent which are both conjugated with antibodies for the antigen and, if the sample includes the antigen, forms magnetic immunocomplexes. The sample tube is attached to a base having a visualization chamber, the sample is flowed into the base from the sample tube, and the magnetic beads and, if formed, the magnetic immunocomplexes are advanced into the visualization window. A second visualization reagent adapted to react with the first visualization reagent to produce a visible change is introduced. An image is acquired of the visualization window with a smartphone to assess whether the visible change has occurred. The image of the visualization window acquired using the smartphone is evaluated to assess whether the antigen is present in the sample.

METHODS OF DETECTING MULTIPLE DISEASE BIOMARKERS

Resumen de: WO2026193586A1

Disclosed herein are methods of detecting at least two biomarkers in a DNA sample from a subject, the method comprising simultaneously, in a single test, amplifying the regions of DNA containing each of the at least two types of biomarkers in the DNA sample to produce amplified DNA; sequencing, by a sequencer, the amplified DNA to produce a sequencing read; and wherein the sequencing read identifies a presence and/or an absence of the at least two types of biomarkers, optionally, outputting a report indicating the presence or absence of the at least two types biomarkers in the DNA sample wherein the at least two types of biomarkers are selected from: (i) single nucleotide variations (SNVs), and/or insertion or deletion (indel) mutations; (ii) chromosomal copy number variations (CNVs), and (iii) gene CNVs.

BINDING MOLECULES TARGETING METHYLPSEUDOURIDINE

Resumen de: WO2026198475A1

The present invention relates to an antigen-binding molecule specifically binding to methylpseudouridine or 1-methyluracil, a polynucleotide encoding it, a conjugate comprising it, and a method for producing such an antigen-binding molecule. The invention further relates to a method for detecting methylpseudouridine or 1-methyluracil, a method for detecting and/or quantifying a level of methylpseudouridine and/or 1-methyluracil, a kit for detecting presence and/or for quantifying a level of methylpseudouridine and/or 1-methyluracil, and a kit for enriching or purifying methylpseudouridine or polynucleotides containing methylpseudouridine.

PROGNOSTIC AND PREDICTIVE VALUE OF ENDOTHELIAL DYSFUNCTION BIOMARKERS IN SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY

Resumen de: US20260287596A1

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the invention relate to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, receiving a dataset comprising biomarker concentrations, wherein the dataset is from a sample obtained from a pediatric patient having at least one indication of septic shock, then determining whether the biomarker concentrations of each of the at least one biomarkers are greater than one or more pre-determined cut-off biomarker concentration, wherein the level of said biomarker correlates with a predicted outcome.

METHOD AND DEVICE FOR ESTIMATING AMOUNT OF TAU PROTEIN ACCUMULATION IN SUBJECT'S BRAIN

Resumen de: US20260287581A1

0000 The present disclosure relates to a method for estimating the amount of a tau protein accumulated in the brain. One of a capture antibody and a detection antibody which are used in the method is an antibody which recognizes an amino acid sequence in a middle part of a phosphorylated tau protein, and the other is an antibody which recognizes a phosphorylated epitope including a phosphorylated amino acid residue of the phosphorylated tau protein.

A METHOD FOR OPTICAL, LABEL-FREE DETECTION OF MOLECULES AT ULTRA-LOW CONCENTRATION, PARTICULARLY AS LOW AS ZEPTOMOLAR CONCENTRATION

Resumen de: US20260287585A1

Detecting a binding event of specific binding pair-forming substances, comprising includes: providing a layer of a first specific binding pair-forming substance (SBPS) on a substrate, providing an enclosure of the layer with a first dielectric medium (DM) rinsing the enclosure for a first time period with a second DM, restoring the first DM in the enclosure following the rinsing, feeding a solution of a second SBPS to the enclosure to cause an interaction between the first second SBPS following the restoring, incubating the enclosure for a second time period, the interaction including a binding event when the first and second SBPS provide a specific binding pair, detecting a shift in a parameter representative of a layer dielectric function following the incubating, comparing the shift with a threshold, whereby when the shift exceeds the threshold the binding event has occurred.

IMPROVED BLOOD DIAGNOSTIC

Resumen de: US20260287598A1

0000 A method to quantify the abundance of Neurofilament light chain (NFL) in a blood sample, comprising the steps of adding a composition comprising a polyanionic molecule and of reacting it with at least one antibody coupled to a detection system, specifically binding to one epitope of the NFL, its use for a diagnostic application and the corresponding diagnostic kit.

GLYCINE RECEPTORS IN WHITE BLOOD CELLS AS BIOMARKERS FOR PAIN

Resumen de: US20260287599A1

Embodiments of the present disclosure pertain to methods of assessing pain in a subject by receiving one or more measured levels of glycine receptors of the subject; and correlating differentially expressed levels of the glycine receptors to pain. The methods of the present disclosure may also include a step of implementing a treatment decision based on the assessment. In some embodiments, the methods of the present disclosure may be repeated after implementing the treatment decision. Additional embodiments of the present disclosure pertain to systems for assessing pain in a subject. In some embodiments, the systems include computer-readable storage mediums with program codes that implement the methods of the present disclosure.

CELLS EXPRESSING PARATHYROID HORMONE 1 RECEPTOR AND USES THEREOF

Resumen de: US20260286293A1

Disclosed herein are pluripotent stem cells cultured with one or more peptide and methods of isolating said stem cells. Also disclosed are methods of targeting the stem cells to a desired region or area within an organism. Also disclosed are methods of using the isolated stem cells for the improvement of fertility, for the promotion of hair growth, for the treatment or prevention of skin conditions, for the treatment or improvement of bone disorders, for the treatment of malignancies, and for the treatment of neurological disorders.

MODIFIED RNA WITH DECREASED IMMUNOSTIMULATORY PROPERTIES

Resumen de: US20260284227A1

The present invention provides a method for providing modified mRNAs of reduced immunogenicity and/or immunostimulatory capacity for use in protein replacement therapy. The invention further provides modified mRNAs and pharmaceutical compositions comprising the modified mRNAs according to the invention for use in protein replacement therapy.

ANTI-TDP-43 BINDING MOLECULES AND USES THEREOF

Resumen de: US20260285956A1

0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).

IMPROVED ANTIBODY SPECIFICALLY BINDING TO AMYLOID-BETA OLIGOMERS

Resumen de: US20260285954A1

The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of the antibody W20. Compared with the antibody W20, the improved form of the antibody W20 has a significantly improved affinity to AβOs, and can more significantly inhibit the aggregation of Aβ and the AβOs-induced toxicity of nerve cells, more effectively improve the cognition and memory functions of an Alzheimer's disease model mouse, and reduce pathological changes in the brain of the mouse. The improved form of the antibody can specifically bind to oligomers of an amyloid-β, α-synuclein, mHTT and SOD 1, can inhibit the aggregation and cytotoxicity of various amyloids, and has a better potential for treating various amyloid diseases, such as Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis, than the antibody W20. The improved form of the antibody can specifically bind to a highly toxic amyloid protein oligomer Aβo*3F, and has a better AD diagnosis value. The amino acid sequence of the antibody W20 is as shown in SEQ ID NO: 1.

COMPOSITIONS AND METHODS FOR DIAGNOSING, TREATING, AND PREVENTING LYSOSOMAL STORAGE DISEASES

Resumen de: US20260286363A1

0000 The present disclosure provides compositions and methods of identifying, making, and using the same for the prevention and treatment of lysosomal storage diseases. Provided are also compositions and methods of diagnosing lysosomal storage diseases.

SYSTEMS FOR IDENTIFYING PROTEOFORMS OF TAU PROTEIN

Resumen de: US20260287600A1

0000 Methods, reagents, kits and systems for analyzing different proteoforms of proteins of interest are provided. The provided methods, systems, etc. provide detection, characterization and quantitation of proteoforms for different biologically relevant proteins for monitoring and characterizing biological processes.

A METHOD FOR REFINED STAGE CLASSIFICATION AND DIAGNOSIS OF A HEREDITARY NEURODEGENERATIVE DISEASE

Resumen de: WO2026196014A1

The invention relates to a method for refined stage classification of a hereditary, preferably monogenic, neurodegenerative diseases mediated by an impairment of a disease-mediating gene, in disease-affected subjects. The invention also relates to diagnosis of a patient with the neurodegenerative diseases comprising classifying said patient in a stage of said disease. The subgroups react differently to treatment. In summary, the present inventors used a preclinical induced neuronal model to predict drug effectiveness in clinical trials, and have found a new dimension on prescreening patients before entering in clinical trials, thereby reducing the trial's failure.

Spatial Proteomics Analysis Using Wavelength-Specific Click Chemistry for Subcellular Resolution Localization

Resumen de: US20260287593A1

The present invention provides methods and systems for antibody-independent spatial proteomics analysis using wavelength-specific click chemistry. Photoactivatable click chemistry reagents responsive to distinct wavelengths (UV, blue, green, red) are introduced into biological samples and selectively activated using laser matrix systems with submicron spatial control. Wavelength-specific activation enables simultaneous labeling of proteins at multiple subcellular locations or tissue regions, followed by mass spectrometry analysis to determine spatial protein distributions with subcellular resolution. The technology eliminates antibody dependencies while providing comprehensive proteome coverage (1000+ proteins per spatial region) at significantly reduced cost and time compared to conventional methods. Applications include clinical cancer diagnostics, drug discovery screening, and research applications across diverse biological systems including cell cultures, tissue sections, and FFPE clinical specimens.

Chemical Carbonylation of Arginine in Peptides and Proteins

Resumen de: US20260285900A1

Disclosed herein are methods of oxidizing a guanidine group comprising contacting a compound or peptide having a guanidine group with a 9,10-phenanthrenequinone or derivative providing compound with an aldehyde group in place of the guanidine group. In certain embodiments, the guanidine group is an arginine amino acid within a protein. In certain embodiments, this disclosure relates to compositions comprising 9,10-phenanthrenequinone derivatives as provided herein.

TEMPORAL TRAUMATIC BRAIN INJURY BIOMARKERS AND METHODS OF USE THEREOF

Resumen de: US20260287601A1

A unique pipeline is employed for biomarker discovery that entailed domain antibody phage display, next generation sequencing analysis, and nanotechnology strategies to generate antibody mimetics are disclosed. Also disclosed are the temporal biomarkers of traumatic brain injury and their methods of use. In some embodiments, the temporal biomarkers are synthetic peptides comprising the HCDR3 sequences identified using the disclosed pipeline. In some aspects, the synthetic peptides have less than 30 amino acid residues and comprise a biotin scaffold that is linked to the HCDR3 sequences.

一种抗BD-Tau抗体或其抗原结合片段及其应用

Resumen de: CN122790090A

0001 本发明涉及生物技术领域，具体涉及抗BD‑Tau蛋白单克隆抗体或其抗原结合片段及其应用。本发明提供的抗体对BD‑Tau蛋白具有高亲和力，能够特异性识别和结合BD‑Tau蛋白，可用于制备BD‑Tau检测试剂或试剂盒，在阿尔茨海默病的早期筛查和诊断中具有重要的应用价值。

脑脊液多肽标志物GHVLAKELE在制备神经梅毒诊断或筛查产品中的应用

Nº publicación: CN122794000A 22/09/2026

Solicitante:

深圳市第三人民医院（深圳市肝病研究所）

Resumen de: CN122794000A

本发明属于生物技术领域，具体涉及一种脑脊液多肽标志物GHVLAKELE在制备神经梅毒诊断或筛查产品中的应用。本发明一种脑脊液多肽标志物GHVLAKELE在制备神经梅毒诊断或筛查产品中的应用，诊断产品是以所述多肽或其特异性结合分子为靶分子的检测试剂盒、抗体芯片、抗体探针或检测仪。本发明克服了现有CSF‑TRUST敏感性低、常规指标特异性差的技术问题，且这种多肽标志物能够准确区分神经梅毒患者与非神经梅毒。